Samanta Cupini

Samanta Cupini

Auto-generated profile, based on publicly available information

Samanta Cupini


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Francesca LessiFrancesca Lessi
Francesca Lessi
MMMariangela Morelli
Mariangela Morelli
Sara FranceschiSara Franceschi
Sara Franceschi
PAPaolo Aretini
Paolo Aretini
MMMichele Menicagli
Michele Menicagli
Chiara Maria MazzantiChiara Maria Mazzanti
Chiara Maria Mazzanti
Circulating tumor cells (CTCs) are one of the most important causes of tumor recurrence and distant metastases. Glioblastoma (GBM) has been considered restricted to the brain for many years. Nevertheless, in the past years, several pieces of evidence indicate that hematogenous dissemination is a reality, and this is also in the caseof GBM. Our aim was to optimize CTCs’ detection in GBM and define the genetic background of single CTCs compared to the primary GBM tumor and its recurrence to demonstrate that CTCs are indeed derived from the parental tumor. We collected blood samples from a recurrent IDH wt GBM patient. We genotyped the parental recurrent tumor tissue and the respective primary GBM tissue. CTCs were analyzed using the DEPArray system. CTCs Copy Number Alterations (CNAs) and sequencing analyses were performed to compare CTCs’ genetic background with the same patient’s primary and recurrent GBM tissues. We identified 210 common mutations in the primary and recurrent tumors. Among these, three somatic high-frequency mutations (in PRKCB, TBX1, and COG5 genes) were selected to investigate their presence in CTCs. Almost all sorted CTCs (9/13) had at least one of the mutations tested. The presence of TERT promoter mutations was also investigated and C228T variation was found in parental tumors and CTCs (C228T heterozygous and homozygous, respectively). We were able to isolate and genotype CTCs from a patient with GBM. We found common mutations but also exclusive molecular characteristics.

16 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
VFValentina Fanotto
Valentina Fanotto
DRDaniele Rossini
Daniele Rossini
MCMariaelena Casagrande
Mariaelena Casagrande
FBFrancesca Bergamo
Francesca Bergamo
ASAndrea Spagnoletti
Andrea Spagnoletti
CCChiara Cremolini
Chiara Cremolini
Background: The decision to resect or not the primary tumor in asymptomatic patients with synchronous metastatic colorectal cancer (mCRC) is a complex and challenging issue for oncologists, especially when an antiangiogenic-based therapy is planned. Methods: Patients enrolled in the phase III TRIBE and TRIBE2 studies that compared upfront FOLFOXIRI + bevacizumab to FOLFIRI or FOLFOX + bevacizumab, respectively, were included. We assessed the association of primary tumor resection (PTR) with progression-free survival (PFS), overall survival (OS), response rate (ORR), rate of grade > 2 adverse events (AEs), and serious gastrointestinal and surgical AEs in the overall population and according to the treatment arm. Results: Of the 999 patients included, 513 (51%) underwent PTR at baseline. Longer PFS and OS were observed in resected patients compared to those with unresected primary tumors: 11.2 vs. 10.0 months (p < 0.001) and 26.6 vs. 22.5 (p < 0.001), respectively. In multivariate models, PTR was confirmed as an independent prognostic factor for better PFS (p = 0.032) and OS (p = 0.018). Patients with PTR experienced a higher incidence of grade 3 or 4 diarrhea (p = 0.055) and lower incidence of anemia (p = 0.053), perforation (p = 0.015), and serious gastrointestinal and surgical AEs (p < 0.001). No statistically significant differences were noted in incidence of bleeding (p = 0.39). The benefit of FOLFOXIRI + bevacizumab in terms of PFS (p for interaction: 0.46), OS (p for interaction: 0.80), ORR (p for interaction: 0.36), and incidence of grade 3 or 4 AEs was independent of PTR. Conclusions: PTR at baseline was independently associated with good prognosis in synchronous mCRC patients and with lower incidence of serious gastrointestinal and surgical AEs during upfront chemotherapy plus bevacizumab. The benefit and toxicity profile of FOLFOXIRI plus bevacizumab was independent of PTR.

28 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ESEnrico Sammarco
Enrico Sammarco
APAntonio Pellino
Antonio Pellino
EBEleonora Bona
Eleonora Bona
AFAzzurra Farnesi
Azzurra Farnesi
EBElisa Biasco
Elisa Biasco
GAGiacomo Allegrini
Giacomo Allegrini
Urothelial carcinoma represents one of the deadliest urological tumors, due to its biological aggressiveness and the ephemeral response to platinum-based chemotherapy of advanced-stage disease. The use of immune checkpoint inhibitors has positively impacted the prognosis of these patients, although only a proportion of them achieve long lasting disease control. As with other solid tumors, in the last decade, there has been a growing interest in the molecular characterization of urothelial carcinoma in order to identify new therapeutic targets and improve survival in these patients. The aim of this narrative review is to summarize the main evidence available in the literature concerning the role of targeted therapies in urothelial carcinoma, especially focusing on related molecular targets, published data on clinical efficacy, and on future perspectives. Specifically, the effort of this review aims to strengthen the clinical impact of well-known molecular patterns and relative target treatments (such as FGFR inhibitors and Nectin-4-directed antibody–drug conjugates) and to examine the role and preliminary data of drugs targeting biomarkers that are not yet commonly used in clinical practice (such as HER2).

9 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GAGiacomo Allegrini
Giacomo Allegrini
GAGiulia Acconci
Giulia Acconci
GMGianna Musettini
Gianna Musettini
LCluigi coltelli
luigi coltelli
CFChiara Finale
Chiara Finale
GBGuido Bocci
Guido Bocci
Cyclin-Dependent Kinase 4/6 inhibitors (CDK 4/6i) represented a paradigm shift in the treatment of patients with metastatic hormone-receptor-positive (HR+), HER2-negative (HER2-) breast cancer patients. When disease progression occurs and further hormonal manipulations or target therapies fail, chemotherapy remains a therapeutic choice. For these reasons, resources should be invested in redesigning the best treatment strategy with the current chemotherapy drugs available. Nevertheless, the preferred strategy typically remains a planned sequence of single chemotherapeutic agents. This approach endeavors to extend overall survival and maintain quality of life. Within this complex and evolving therapeutic scenario, where the necessity for effective and treatment options is crucial, we explore in the present paper a perspective for a hypothetical new role of bevacizumab combined with paclitaxel for patients with metastatic HR+, HER2- breast cancer patients resistant to hormone therapy. Recent findings from our preliminary published pharmacogenetic studies, could suggest the efficacy of bevacizumab as linked to a well-defined genomic profile of genes implicated in the process of neoangiogenesis (e.g., favorable profile: VEGF-A rs833061/VEGFR-2 rs1870377: CT/AT, CT/AA, TT/AA, TT/TT, CC/TT), concluding the present perspective underlying the fact that bevacizumab combined with paclitaxel will be reconsidered with this new potential use only if well-designed prospective trials confirm what has been observed from our retrospective data.